Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$65.94 - $99.04 $432,302 - $649,306
6,556 Added 9.65%
74,529 $5.08 Million
Q2 2023

Aug 11, 2023

BUY
$62.68 - $95.05 $4.06 Million - $6.15 Million
64,699 Added 1976.15%
67,973 $6.38 Million
Q1 2023

May 15, 2023

SELL
$47.19 - $70.77 $425,040 - $637,425
-9,007 Reduced 73.34%
3,274 $222,000
Q4 2022

Feb 13, 2023

BUY
$30.35 - $53.15 $372,728 - $652,735
12,281 New
12,281 $608,000
Q2 2022

Aug 11, 2022

BUY
$35.61 - $76.23 $280,571 - $600,616
7,879 New
7,879 $310,000
Q2 2021

Aug 12, 2021

SELL
$93.66 - $139.27 $586,967 - $872,805
-6,267 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$116.57 - $155.01 $523,865 - $696,614
4,494 Added 253.47%
6,267 $826,000
Q4 2020

Feb 11, 2021

BUY
$99.61 - $142.12 $176,608 - $251,978
1,773 New
1,773 $235,000
Q3 2020

Nov 06, 2020

SELL
$72.92 - $102.01 $850,028 - $1.19 Million
-11,657 Closed
0 $0
Q2 2020

Aug 07, 2020

BUY
$55.75 - $92.75 $649,877 - $1.08 Million
11,657 New
11,657 $1.01 Million
Q1 2019

May 13, 2019

SELL
$61.98 - $96.5 $1.65 Million - $2.57 Million
-26,593 Closed
0 $0
Q4 2018

Feb 13, 2019

BUY
$56.04 - $82.66 $1.49 Million - $2.2 Million
26,593 New
26,593 $1.68 Million
Q3 2018

Nov 09, 2018

SELL
$48.29 - $80.6 $3.86 Million - $6.44 Million
-79,874 Closed
0 $0
Q2 2018

Aug 07, 2018

BUY
$37.84 - $69.96 $3.02 Million - $5.59 Million
79,874 New
79,874 $4.78 Million
Q1 2018

May 03, 2018

SELL
$39.82 - $57.53 $629,793 - $909,894
-15,816 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$46.49 - $60.51 $170,664 - $222,132
3,671 Added 30.23%
15,816 $831,000
Q3 2017

Nov 09, 2017

BUY
$37.05 - $47.12 $449,972 - $572,272
12,145
12,145 $572,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.1B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Trexquant Investment LP Portfolio

Follow Trexquant Investment LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

News

Stay updated on Trexquant Investment LP with notifications on news.